Literature DB >> 16301813

Identification of an HLA-A24-restricted OY-TES-1 epitope recognized by cytotoxic T-cells.

Hideo Okumura1, Yuji Noguchi, Akiko Uenaka, Toshiki Aji, Toshiro Ono, Kazuhiko Nakagawa, Motoi Aoe, Nobuyoshi Shimizu, Eiichi Nakayama.   

Abstract

OY-TES-1 was identified as a human homologue of the mouse, guinea pig, and pig proacrosin binding protein sp32 precursor. Differential expression levels of OY-TES-1 mRNA between testis and other normal tissues, and its expression in cancers indicated that OY-TES-1 would be classified as a cancer/testis antigen and considered to be a candidate of target antigen for cancer immunotherapy. In this study, we showed identification of HLA-A24-binding OY-TES-1 peptide, TES(401-409) (KTPFVSPLL) recognized by CD8 T-cells. Purified CD8 T-cells from healthy donors stimulated in vitro with the peptide-pulsed autologous DC and PBMC produced IFNgamma in response to the peptide-pulsed PBMC and showed cytotoxicity against the peptide-pulsed autologous EBV-B specifically. Furthermore, cytotoxicity was also observed against an OY-TES-1 mRNA-expressing tumor line, LK79. The retention time of the fraction in HPLC of the acid eluate from LK79 cells that showed positive sensitization against autologous EBV-B cells in recognition by CD8 CTL was the same as that of the fraction of the TES(401-409) peptide itself, suggesting that the TES(401-409) was a naturally processed peptide on LK79.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16301813     DOI: 10.1111/j.1348-0421.2005.tb03688.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  7 in total

1.  Tumor antigen acrosin binding protein normalizes mitotic spindle function to promote cancer cell proliferation.

Authors:  Angelique W Whitehurst; Yang Xie; Scott C Purinton; Kathryn M Cappell; Jackie T Swanik; Brittany Larson; Luc Girard; John O Schorge; Michael A White
Journal:  Cancer Res       Date:  2010-09-28       Impact factor: 12.701

2.  Cancer testis antigen OY-TES-1 expression and serum immunogenicity in colorectal cancer: its relationship to clinicopathological parameters.

Authors:  Bin Luo; Xiang Yun; Rong Fan; Yong-Da Lin; Shu-Jia He; Qing-Mei Zhang; Fa-Rong Mo; Fang Chen; Shao-Wen Xiao; Xiao-Xun Xie
Journal:  Int J Clin Exp Pathol       Date:  2013-11-15

3.  Down-regulation of cancer/testis antigen OY-TES-1 attenuates malignant behaviors of hepatocellular carcinoma cells in vitro.

Authors:  Jun Fu; Bin Luo; Wen-Wen Guo; Qing-Mei Zhang; Lei Shi; Qi-Ping Hu; Fang Chen; Shao-Wen Xiao; Xiao-Xun Xie
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

4.  Serum immunoreactivity of cancer/testis antigen OY-TES-1 and its tissues expression in glioma.

Authors:  Xisheng Li; Jun Yan; Rong Fan; Bin Luo; Qingmei Zhang; Yongda Lin; Sufang Zhou; Guorong Luo; Xiaoxun Xie; Shaowen Xiao
Journal:  Oncol Lett       Date:  2017-03-03       Impact factor: 2.967

5.  Immunohistochemistry Study of OY-TES-1 Location in Fetal and Adult Human Tissues.

Authors:  Jun Fu; Yongda Lin; Chang Liu; Weixia Nong; Xin Luo; Shaowen Xiao; Xiaoxun Xie; Bin Luo
Journal:  J Healthc Eng       Date:  2022-04-13       Impact factor: 3.822

6.  Detection of sperm-reactive antibodies in wild sika deer and identification of the sperm antigens.

Authors:  Osamu Kawase; Mitsuru Jimbo
Journal:  J Vet Med Sci       Date:  2018-03-16       Impact factor: 1.267

7.  Cancer-testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis.

Authors:  Lina Lin; Weixia Nong; Bin Luo; Yingying Ge; Xia Zeng; Feng Li; Rong Fan; Qingmei Zhang; Xiaoxun Xie
Journal:  Immun Inflamm Dis       Date:  2021-09-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.